Baxter this week issued another update on its progress in alleviating temporary supply constraints for its blood pressure cuffs.
The medical device maker said its BP cuff manufacturing operations remain at 100% production on a 24/7 schedule, producing volumes and shipments consistent with what it called pre-disruption amounts.
Most Read Medical News:
- Department of Health and Human Services Will Cut 10,000 Jobs
- 5 Minutes with MDD: Allison Harbaugh, Medical Business Manager at Stratasys
- Calyxo Issues Urinary Stone Device Warning After Patient Death
- New Material Allows Patients to Adjust Prosthetic Limbs Using a Smartphone
It also said that it has made significant progress in its capacity expansion plan, including the installation of one blood pressure cuff machine in the U.S., which has been fully operational and shipping cuffs since March 14. Baxter expects this machine will be followed by another U.S.-based product machine that it expects to be fully operational in late May.
"As previously communicated, these capital equipment investments and diversification of our manufacturing locations will support the acceleration of our backlog recovery and our supply agility going forward," the company wrote.
As of March 28, Baxter's highest volume cuffs, FlexiPort Standardization/RAW Soft, have been removed from allocation. The company shared that the FlexiPort Fully-Configured cuffs, the only remaining cuffs on allocation, are expected to be removed from allocation in mid-April.
Baxter last year said it was experiencing a temporary constraint on raw material availability for its blood pressure cuff production out of its manufacturing plant in Mexico. That comes after U.S. imports of raw materials into Mexico were temporarily halted, which led to a pause in production at its plant.
Click here to subscribe to our daily newsletter featuring medical manufacturing industry news.
